Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.75, $0.04 better than the analyst estimate of $0.71. Revenue for the quarter came in at $5.07 billion versus the consensus estimate of $4.97 billion.

GUIDANCE:

Boston Scientific sees Q4 2025 EPS of $0.77-$0.79, versus the consensus of $0.76.

Boston Scientific sees FY2025 EPS of $3.02-$3.04, versus the consensus of $2.98.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.